Observational studyBMC cardiovascular disorders2026
Clinical characteristics, antithrombotic strategies, and outcomes in patients with atrial fibrillation and coronary heart disease undergoing percutaneous coronary intervention: a multicenter real-world study in Chongqing, China.
Observational study in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAtrial fibrillation (AF) with coronary artery disease (CAD) requiring percutaneous coronary intervention (PCI) - including both acute and chronic presentations - is common, yet the optimal antithrombotic regimen remains unclear. This study aimed to characterize clinical features, current antithrombotic therapy, and discharge prognosis in this population.
methodsData were collected from three independent annual cohorts of patients with atrial fibrillation and coronary heart disease undergoing PCI (2013, 2018, and 2023). First, cross-sectional comparisons across the three years were performed to examine temporal trends in clinical characteristics and discharge antithrombotic therapy. Predictors of discharge antithrombotic therapy were then analyzed in the 2023 cohort. Second, the 2023 cohort was prospectively followed for a median of 17 months (interquartile range 9-24 months; range 0.5-32 months) to evaluate clinical outcomes according to different antithrombotic regimens and to identify independent risk factors.
resultsOf the 1,062 participants, 479 underwent longitudinal follow-up (median 17 months, IQR 9-24; range 0.5-32). Independent predictors of intensified antithrombotic therapy included recent PCI, proton pump inhibitor use, and statin use; independent predictors of antiplatelet therapy included recent PCI, age, liver dysfunction, left atrial diameter, proton pump inhibitor use, heart failure, and non-paroxysmal atrial fibrillation. During follow-up, anticoagulant therapy showed a trend toward higher MACCEs risk compared with intensified antithrombotic therapy (HR 1.47, 95% CI 0.97-2.24, P=0.073) and antiplatelet therapy (HR 1.33, 95% CI 0.79-2.22, P=0.280), with no significant difference between the latter two (HR 1.15, 95% CI 0.71-1.88, P=0.567). Multivariate Cox regression identified liver dysfunction, diabetes, and HAS-BLED score as independently associated with MACCEs, while higher hemoglobin and statin use were associated with lower risk.
conclusionsOver the years, more AF with CHD patients after PCI received post-discharge antithrombotic therapy. Liver dysfunction, diabetes, and a high HAS‑BLED score were independently associated with MACCEs, while statin use was associated with lower risks of all‑cause death, MI, and ischemia‑driven revascularization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.